Just because of a few sick patients' allergic reaction to a "good" drug. Here we have cigarettes and acohol killing hundreds of thousands of people, innocents alike, each and every year and the government continue to look the other way. Not fair, but who says life has to be fair? I wish all of Affymax's employees the best of luck in rebuiling their future.
What a coincident! I was a dealer at Harrahs Rincon (4 years). But I don't play the house games. I know better! Poker is fine, I guess, because we're playing against one another.
If you have to ask, you can't afford it. If you're worrying about how much it would drop if Zohydro's rejected, then biotech is definitely the wrong game for you. Go and invest in brick and mortar stocks. I am here because it makes my blood travels up and down my veins 100 miles an hour and that's just the way I like it.
The pps will continue to go down without any significant news. We might see 1.70 before the FDA's decision. I am holding on to my shares and shorts can have them over my dead body!
I think it will immediately jump to 5 and then the day traders take over. Just look at SOMX, jumped to 18 within a month from a buck or so and its drug is no where near the market for Zohydro.
But because I just saw a picture of the Samsung Galaxy S4 and the darn thing is downright ugly! The Blackberry Z10 will beat the Galaxy 4 hands down and both legs tied behind its back.
lol...If the decision has been leaked, you would think that it's already gone up over 100% instead of just a measly 10%.
Tell that to my landlord, who I pay my rent to and Albertsons, where I usually shop for grocery for my family.
Most likely, zohydro will be approved and classified as a schedule II drug. But there's also a good chance of it being a schedule III and that is why the FDA's delaying its decision, imo. I have gout and don't want to take acetaminophen for pain, unless it's absolutely necessary. I'd rather deal with the pain than having my liver bleeding from acetaminophen. Zohydro will be my life saver! With a 635 billion dollar market for chronic pain drugs, there's plenty of room to grow for Zohydro, even being classified as a schedule II.